CLINICAL AND EXPERIMENTAL USE OF t-AMCHA IN UROLOGY

Abstract

We were investigated clinical and experimental use of t-AMCHA which was synthesized as a new more potent inhibitor of fibrinolysis than EACA.
1. On the treatment for the diseases caused fibrinolysis or with fibrinolysis, t-AMCHA was effective, as if to be observed on the so-called idiopathic renal bleeding.
2. On a prophylactic for the side effect of the injection of streptomycin to a fifth cerebral nerve and a favorable turn of the irritation symptome of the urinary bladder by pouring into the urinary bladder on the cystitis, t-AMCHA had more week effect than EACA and mixed-AMCHA.
3. The inhibitory effect of t-AMCHA to fibrinolysis of urine (human and rabbit) was more potent than EACA.
4. The inhibitory effect of t-AMCHA to fibrinolysis of trypsin was also more potent than EACA.
5. On the inhibitory effect of capillary osmotic substances, the different substances had most potent inhibitory effect severally, namely, t-AMCHA had that to leucotaxin-like substance, mixed-AMCHA had to bradykinin (Sandoz), and EACA had that to serotonin.
But this studies would more to be investigated.